Cargando…

Long-term benefits of physical activity in adult patients with late onset Pompe disease: a retrospective cohort study with 10 years of follow-up

BACKGROUND: In 2011 a 12 weeks personalized exercise training program in 23 mildly affected adult late onset Pompe patients (age 19.6–70.5 years) improved endurance, muscle strength and function. Data on long-term effects of this program or of other physical activity in Pompe disease are absent. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ismailova, Gamida, Wagenmakers, Margreet A. E. M., Brusse, Esther, van der Ploeg, Ans T., Favejee, Marein M., van der Beek, Nadine A. M. E., van den Berg, Linda E. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566098/ https://www.ncbi.nlm.nih.gov/pubmed/37821981 http://dx.doi.org/10.1186/s13023-023-02924-x

Ejemplares similares

Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions
por: Ditters, Imke A. M., et al.
Publicado: (2023)

Is the brain involved in patients with late‐onset Pompe disease?
por: van den Dorpel, Jan J. A., et al.
Publicado: (2022)

Association of Muscle Strength and Walking Performance in Adult Patients With Pompe Disease
por: Favejee, Marein M, et al.
Publicado: (2018)

Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study
por: Ditters, Imke A. M., et al.
Publicado: (2023)

Mild disease course of SARS-CoV-2 infections and mild side effects of vaccination in Pompe disease: a cohort description
por: Ismailova, G., et al.
Publicado: (2022)

Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study
por: Yuan, Meng, et al.
Publicado: (2020)

Are Anti-rhGAA Antibodies a Determinant of Treatment Outcome in Adults with Late-Onset Pompe Disease? A Systematic Review
por: Ditters, Imke A. M., et al.
Publicado: (2023)

Effects of exercise training in 23 adults with Pompe disease receiving enzyme therapy
por: van den Berg, Linda, et al.
Publicado: (2013)

Phenotypical variation within 22 families with Pompe disease
por: Wens, Stephan C A, et al.
Publicado: (2013)

MRI changes in diaphragmatic motion and curvature in Pompe disease over time
por: Harlaar, Laurike, et al.
Publicado: (2022)

Hearing in adults with Pompe disease
por: van der Beek, Nadine A. M. E., et al.
Publicado: (2011)

Safety and efficacy of exercise training in adults with Pompe disease: evalution of endurance, muscle strength and core stability before and after a 12 week training program
por: van den Berg, Linda E. M., et al.
Publicado: (2015)

Chest MRI to diagnose early diaphragmatic weakness in Pompe disease
por: Harlaar, Laurike, et al.
Publicado: (2021)

Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease
por: Harlaar, Laurike, et al.
Publicado: (2019)

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients
por: van der Meijden, Jan C., et al.
Publicado: (2018)

Fatigue: an important feature of late-onset Pompe disease
por: Hagemans, M. L. C., et al.
Publicado: (2007)

Enzyme replacement therapy and fatigue in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
por: van der Meijden, Jan C., et al.
Publicado: (2018)

A genetic modifier of symptom onset in Pompe disease
por: Bergsma, Atze J., et al.
Publicado: (2019)

Burden of illness of Pompe disease in patients only receiving supportive care
por: Kanters, Tim A., et al.
Publicado: (2011)

Diffusion tensor imaging of the brain in Pompe disease
por: van den Dorpel, Jan J. A., et al.
Publicado: (2022)

Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism
por: Canibano‐Fraile, Rodrigo, et al.
Publicado: (2022)

Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease
por: van Kooten, Harmke A., et al.
Publicado: (2022)

Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease
por: Schaaf, Gerben J., et al.
Publicado: (2015)

Extension of the Pompe mutation database by linking disease‐associated variants to clinical severity
por: Niño, Monica Y., et al.
Publicado: (2019)

Increased aortic stiffness and blood pressure in non-classic Pompe disease
por: Wens, Stephan C. A., et al.
Publicado: (2014)

Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long‐term clinical outcome of classic infantile Pompe patients
por: Poelman, Esther, et al.
Publicado: (2020)

The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients
por: van Capelle, Carine I., et al.
Publicado: (2011)

Neurofilament Light and Its Association With CNS Involvement in Patients With Classic Infantile Pompe Disease
por: Mackenbach, Maarten J., et al.
Publicado: (2023)

Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
por: Dimachkie, Mazen M., et al.
Publicado: (2022)

Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience
por: Niño, Monica Y., et al.
Publicado: (2020)

The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease
por: Kuperus, Esther, et al.
Publicado: (2018)

PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease
por: Hagemans, Marloes L. C., et al.
Publicado: (2010)

A conceptual disease model for adult Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2015)

Late-Onset Pompe Disease with Nemaline Bodies
por: Frezza, E., et al.
Publicado: (2018)

Minutes of the European POmpe Consortium (EPOC) Meeting March 27 to 28, 2015, Munich, Germany
por: Schoser, Benedikt, et al.
Publicado: (2015)

Impact of enzyme replacement therapy on survival in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

Antisense Oligonucleotides Promote Exon Inclusion and Correct the Common c.-32-13T>G GAA Splicing Variant in Pompe Disease
por: van der Wal, Erik, et al.
Publicado: (2017)

Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start
por: Stockton, David W., et al.
Publicado: (2020)

Newborn screening for pompe disease? a qualitative study exploring professional views
por: van El, Carla G, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_drja0379591tipcd4p0d410hh4